Cancer Research and Treatment

Original Articles

Lung Cancer

Conditional Survival of Surgically Treated Patients with Lung Cancer: A Comprehensive Analyses of Overall, Recurrence-free, and Relative Survival: Dong Wook Shin, Jong Ho Cho, Jung Eun Yoo, Juhee Cho, Dong Woog Yoon, Genehee Lee, Sumin Shin, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Jae Ill Zo, Young Mog Shim; Cancer Res Treat. 2021;53(4):1057-1071. Published online March 9, 2021; DOI: https://doi.org/10.4143/crt.2020.1308

Purpose
Survival probability changes over time in cancer survivors. This study examined conditional survival in patients undergoing curative resection for non-small cell lung cancer (NSCLC).
Materials and Methods
Five-year conditional recurrence-free survival (CRFS), conditional overall survival (COS), and conditional relative survival (CRS) up to 10 years after surgery were calculated in patients who underwent NSCLC resection from 1994 to 2016. These rates were stratified according to age, sex, year of diagnosis, pathological stage, tumor histology, smoking status, comorbidity, and lung function.
Results
Five-year CRFS increased from 65.6% at baseline to 90.9% at 10 years after surgery. Early differences in 5-year CRFS according to stratified patient characteristics disappeared, except for age: older patients exhibited persistently lower 5-year CRFS. Five-year COS increased from 72.7% to 78.3% at 8 years and then decreased to 75.4% at 10 years. Five-year CRS increased from 79.0% at baseline to 86.8% at 10 years. Older age and higher pathologic stage were associated with lower 5-year COS and CRS up to 10 years after surgery. Female patients, those with adenocarcinoma histology, non-smokers, patient without comorbidities and had good lung function showed higher COS and CRS.
Conclusion
CRFS improved over time, but significant risk remained after 5 years. CRS slightly improved over time but did not reach 90%, suggesting significant excess mortality compared to the general population. Age and stage remained significant predictors of conditional survival several years after surgery. Our conditional survival estimates should help clinicians and patients make informed treatment and personal life decisions based on survivorship status.

Citations

Citations to this article as recorded by

A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United States
Amy L. Cummings, Jesse Sussell, Katherine L. Rosettie, Fadoua El Moustaid, Sarika Ogale, Celina Ngiam, Nick Jovanoski, Melina Arnold, Jay M. Lee
American Journal of Clinical Oncology.2026; 49(5): 205. CrossRef
Leveraging Landmark Analysis for Tailored Surveillance in Stage I Non-Small-Cell Lung Cancer
Giovanni Leuzzi, Federica Sabia, Matteo Calderoni, Clarissa Uslenghi, Ugo Pastorino, Alfonso Marchianò, Michele Ferrari, Alessandro Pardolesi, Daniele Lorenzini, Giuseppe Lo Russo, Claudia Proto, Arsela Prelaj, Piergiorgio Solli
Cancers.2026; 18(3): 367. CrossRef
Conditional survival after curative resection for extrahepatic cholangiocarcinoma: a comprehensive analysis of overall, recurrence-free, and relative survival
Hea Lim Choi, Danbee Kang, In Woon Han, Hong Kwan Kim, Hyeong Seok Kim, Sang Hyun Shin, Jin Seok Heo, Dong Wook Shin, Hongbeom Kim
HPB.2026;[Epub] CrossRef
CT-Based Radiomics Predicts the Functional State of Tumor-Infiltrating CD8+ T Cells and Prognosis in NSCLC
Baojun Sang, Xiaoyu Zang, Jingkai Yu, Liying Yang, Guanqun Yang, Xiaodan Geng, Mei Zheng, Haoran Qi, Qingtao Qiu, Fanghan Cao, Ligang Xing, Xiaorong Sun
Academic Radiology.2026; 33(5): 2293. CrossRef
Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the ‘EVIDENCE’ study
Giannis Mountzios, Sofia Lampaki, Helena Linardou, Vassilis Georgoulias, Dimitrios Mavroudis, Stavros Anevlavis, Andriani Charpidou, Maria Lykka, Dionysis Spyratos, Evangelos G Sarris, Alvertos Somarakis, Christina Papista, Alexandros Glentis, Aristeidis
Future Oncology.2025; 21(4): 447. CrossRef
COL3A1‐positive endothelial cells influence LUAD prognosis and regulate LUAD carcinogenesis by NCL–PI3K–AKT axis
Moyan Zhang, Yicheng Liang, Peng Song
The Journal of Gene Medicine.2024;[Epub] CrossRef
Adjustment to “new normal” after cancer among non–small cell lung cancer survivors: A qualitative study
Genehee Lee, Soo Yeon Kim, Alice Ahn, Sunga Kong, Heesu Nam, Danbee Kang, Hong Kwan Kim, Young Mog Shim, Ansuk Jeong, Dong Wook Shin, Juhee Cho
Palliative and Supportive Care.2024; 22(3): 487. CrossRef
Spatial features of specific CD103+CD8+ tissue-resident memory T cell subsets define the prognosis in patients with non-small cell lung cancer
Guanqun Yang, Siqi Cai, Mengyu Hu, Chaozhuo Li, Liying Yang, Wei Zhang, Jujie Sun, Fenghao Sun, Ligang Xing, Xiaorong Sun
Journal of Translational Medicine.2024;[Epub] CrossRef
Supporting Life Adjustment in Patients With Lung Cancer Through a Comprehensive Care Program: Protocol for a Controlled Before-and-After Trial
Wonyoung Jung, Alice Ahn, Genehee Lee, Sunga Kong, Danbee Kang, Dongok Lee, Tae Eun Kim, Young Mog Shim, Hong Kwan Kim, Jongho Cho, Juhee Cho, Dong Wook Shin
JMIR Research Protocols.2024; 13: e54707. CrossRef
Conditional Survival of Patients with Limited-Stage Small Cell Lung Cancer After Surgery: A National Real-World Cohort Study
Jun-Peng Lin, Xiao-Feng Chen, Peiyuan Wang, Hao He, Wei-Jie Chen, Feng-Nian Zhuang, Hang Zhou, Yu-Jie Chen, Wen-Wei Wei, Shuo-Yan Liu, Feng Wang
Annals of Surgical Oncology.2024; 31(7): 4250. CrossRef
Cost‐Effectiveness Analysis of Adjuvant Alectinib versus Platinum‐Based Chemotherapy in Resected ALK‐Positive Non‐Small‐Cell Lung Cancer in the Chinese Health Care System
Qiran Wei, Yifang Liang, Jiahui Mao, Xin Guan
Cancer Medicine.2024;[Epub] CrossRef
Bioinformatics-based modeling of lung squamous cell carcinoma prognosis and prediction of immunotherapy response
Qiqing Zhang, Haidong He, Yi Wei, Guoping Li, Lu Shou
Discover Oncology.2024;[Epub] CrossRef
Dynamic evaluation of postoperative survival in intrahepatic cholangiocarcinoma patients who did not undergo lymphadenectomy: a multicenter study
Tingfeng Huang, Jie Kong, Hongzhi Liu, Zhipeng Lin, Qizhu Lin, Jianying Lou, Shuguo Zheng, Xinyu Bi, Jianming Wang, Wei Guo, Fuyu Li, Jian Wang, Yamin Zheng, Jingdong Li, Shi Cheng, Weiping Zhou, Yongyi Zeng
Scandinavian Journal of Gastroenterology.2023; 58(2): 178. CrossRef
A2aR on lung adenocarcinoma cells: A novel target for cancer therapy via recruiting and regulating tumor-associated macrophages
Ying Bai, Xin Zhang, Jiawei Zhou, Jianqiang Guo, Yafeng Liu, Chao Liang, Wenyang Wang, Yingru Xing, Jing Wu, Dong Hu
Chemico-Biological Interactions.2023; 382: 110543. CrossRef
Survival and Quality-of-life Outcomes in Early-Stage NSCLC Patients: a Literature Review of Real-World Evidence
Nick Jovanoski, Kathleen Bowes, Audrey Brown, Rossella Belleli, Danilo Di Maio, Shkun Chadda, Seye Abogunrin
Lung Cancer Management.2023;[Epub] CrossRef
Conditional survival analysis of patients with resected non–small cell lung cancer
Talib Chaudhry, Vaishnavi Krishnan, Andrew E. Donaldson, Zachary M. Palmisano, Sanjib Basu, Nicole M. Geissen, Justin M. Karush, Gillian C. Alex, Jeffrey A. Borgia, Michael J. Liptay, Christopher W. Seder
JTCVS Open.2023; 16: 948. CrossRef
Clinical Value of Surveillance 18F-fluorodeoxyglucose PET/CT for Detecting Unsuspected Recurrence or Second Primary Cancer in Non-Small Cell Lung Cancer after Curative Therapy
Chae Hong Lim, Soo Bin Park, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Yong Chan Ahn, Myung-ju Ahn, Joon Young Choi
Cancers.2022; 14(3): 632. CrossRef
Primary care‐based lung and breast cancer control in China: A commentary on lessons learnt from Korea
Heng Piao, Harry H. X. Wang, Hyejin Lee, Mingyang Yu, Belong Cho
European Journal of Cancer Care.2022;[Epub] CrossRef
Conditional survival nomogram predicting real-time prognosis of locally advanced breast cancer: Analysis of population-based cohort with external validation
Xiangdi Meng, Furong Hao, Zhuojun Ju, Xiaolong Chang, Yinghua Guo
Frontiers in Public Health.2022;[Epub] CrossRef

9,881 View
186 Download
18 Web of Science
19 Crossref

Pediatric malignancy

Genome-Wide Association Study for the Identification of Novel Genetic Variants Associated with the Risk of Neuroblastoma in Korean Children: Joon Seol Bae, Ji Won Lee, Jung Eun Yoo, Je-Gun Joung, Keon Hee Yoo, Hong Hoe Koo, Yun-Mi Song, Ki Woong Sung; Cancer Res Treat. 2020;52(4):1251-1261. Published online June 30, 2020; DOI: https://doi.org/10.4143/crt.2020.140

Abstract PDF Supplementary Material PubReader ePub

Purpose
Neuroblastoma (NB) is the most common extracranial solid tumor found in children. To identify significant genetic factors for the risk of NB, several genetic studies was conducted mainly for Caucasians and Europeans. However, considering racial differences, there is a possibility that genetic predispositions that contribute to the development of NB are different, and GWAS study has not yet been conducted on Korean NB patients.
Materials and Methods
To identify the genetic variations associated with the risk of pediatric NB in Korean children, we performed a genome-wide association analysis with 296 NB patients and 1000 unaffected controls (total n = 1,296) after data cleaning and filtering as well as imputation of non-genotyped SNPs using IMPUTE v2.3.2.
Results
After adjusting for multiple comparisons, we found 21 statistically significant SNPs associated with the risk of NB (P^corr < 0.05) within 12 genes (RPTN, MRPS18B, LRRC45, KANSL1L, ARHGEF40, IL15RA, L1TD1, ANO7, LAMA5, OR7G2, SALL4, and NEUROG2). Interestingly, out of these, 12 markers were nonsynonymous SNPs. The SNP rs76015112 was most significantly associated with the risk of NB (p = 8.1E-23, P^corr = 2.3E-17) and was located in the RPTN gene. In addition, significant nonsynonymous SNPs in ADGRE1 were found in patients with MYCN amplification (rs7256147, p = 2.6E-05). In high-risk group, rs7256147 was observed as a significant SNP (p = 5.9E-06).
Conclusion
Our findings might facilitate improved understanding of the mechanism of pediatric NB pathogenesis. However, functional evaluation and replication of these results in other populations are still needed.

Citations

Citations to this article as recorded by

Expression of anoctamin 7 (ANO7) is associated with poor prognosis and mucin 2 (MUC2) in colon adenocarcinoma: a study based on TCGA data
Chen Chen, Siripat Aluksanasuwan, Keerakarn Somsuan
Genomics & Informatics.2023; 21(4): e46. CrossRef
An Overview of Long Non-Coding (lnc)RNAs in Neuroblastoma
Francesca Baldini, Matilde Calderoni, Laura Vergani, Paola Modesto, Tullio Florio, Aldo Pagano
International Journal of Molecular Sciences.2021; 22(8): 4234. CrossRef

9,184 View
156 Download
10 Web of Science
2 Crossref

First
Prev
Page of 1
Next
Last

Search